On Tuesday the 16th and Wednesday the 17th of April, the European Medicines Agency (EMA) hosted a meeting in Amsterdam, “Multi-stakeholder workshop on psychedelics – Towards an EU regulatory framework”.
Heavy rain and strong winds earlier in the week stunted Schiphol Airport’s capacity, making it a bad trip for some. Still, those attendees that made it to Amsterdam included academics, representatives from drug developers, lawyers, and so on.
Here, we don’t aim to provide a blow-by-blow account of the meeting, but instead share some thematic notes. I also focus more on the Q&A or interactive elements of the workshop, as those are generally where new information or angles are found.
In this Dispatch:
- Regulatory Remits
- Disentangling Pharmacotherapy from Psychotherapy
- Standardisation and Its Discontents
- Standardising Extra-Pharmacological Elements of Psychedelic Studies
- Standardising Adverse Event Definition and Reporting
- Blinding
- Indication Sequencing: TRD vs. MDD
- Safety & Post-Trial Support
- Relationship Between Subjective Effects and Therapeutic Outcomes
- Deficiencies in Present Data
- Predicting Treatment Response
- Rescheduling
- Incentivising Psychedelic Drug Development in the EU
Please sign in to your Pα+ account to read the full article…
This article is exclusively for Pα+ subscribers. Head to our Join page to learn more, or sign in to your account.
Select organisations mentioned in this article: Cybin; Compass Pathways; GH Research; PsyPAN; PsyPal; EFPIA; PAREA; Clerkenwell Health; Lykos Therapeutics; European Medicines Agency (EMA); Food and Drug Administration (FDA).